A detailed history of Deka Bank Deutsche Girozentrale transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Deka Bank Deutsche Girozentrale holds 20,000 shares of RCUS stock, worth $297,400. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,000
Previous 20,000 -0.0%
Holding current value
$297,400
Previous $364,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 01, 2023

SELL
$19.7 - $35.71 $453,100 - $821,330
-23,000 Reduced 53.49%
20,000 $405,000
Q1 2022

Apr 28, 2022

BUY
$28.92 - $41.83 $112,788 - $163,137
3,900 Added 9.97%
43,000 $1.44 Million
Q4 2021

Feb 02, 2022

BUY
$31.38 - $48.47 $34,518 - $53,317
1,100 Added 2.89%
39,100 $1.65 Million
Q3 2021

Oct 22, 2021

BUY
$26.93 - $37.68 $1.02 Million - $1.43 Million
38,000 New
38,000 $1.31 Million

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.07B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Deka Bank Deutsche Girozentrale Portfolio

Follow Deka Bank Deutsche Girozentrale and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

News

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.